Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) attaches a copy of its presentation to analysts and fund managers.
This presentation supports the company’s financial results for the full year ended 31 March 2015 which were released on 29 May 2015.
The presentation will also be made available on the company’s website, www.fphcare.com in the Investor Section, Presentations.
Contact: Marcus Driller, Investor Relations & Corporate Affairs Manager on +64 9 574 0110
FY2015 Full Year Update
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment